NCT02059434View on ClinicalTrials.gov

Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD

PHASE1CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

September 1, 2013

Primary Completion Date

October 6, 2014

Study Completion Date

October 6, 2014

Conditions
Chronic Obstructive Pulmonary Disease (COPD)Asthma
Interventions
DRUG

LAS190792 Dose 1

DRUG

LAS190792 Dose 2

DRUG

LAS190792 Dose 3

DRUG

LAS190792 Dose 4

DRUG

LAS190792 Dose 5

DRUG

LAS190792 Dose 6

DRUG

LAS190792 Dose 1 (Part 2)

DRUG

LAS190792 Dose 2 (Part 2)

DRUG

Tiotropium 18 μg

DRUG

Indacaterol 150 μg

DRUG

Placebo

Trial Locations (2)

SE1 1YR

Quintiles Drug Research Unit at Guy's Hospital, London

M23 9QZ

Medicines Evaluation Unit Ltd (MEU), Manchester

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT02059434 - Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD | Biotech Hunter | Biotech Hunter